HomeCompareARHLF vs MRK

ARHLF vs MRK: Dividend Comparison 2026

ARHLF yields 4081.63% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARHLF wins by $8719444271720.61M in total portfolio value
10 years
ARHLF
ARHLF
● Live price
4081.63%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8719444271720.67M
Annual income
$8,318,530,940,671,060,000.00
Full ARHLF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — ARHLF vs MRK

📍 ARHLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARHLFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARHLF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARHLF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARHLF
Annual income on $10K today (after 15% tax)
$346,938.78/yr
After 10yr DRIP, annual income (after tax)
$7,070,751,299,570,401,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, ARHLF beats the other by $7,070,751,299,570,393,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARHLF + MRK for your $10,000?

ARHLF: 50%MRK: 50%
100% MRK50/50100% ARHLF
Portfolio after 10yr
$4359722135860.36M
Annual income
$4,159,265,470,335,535,000.00/yr
Blended yield
95.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ARHLF
No analyst data
Altman Z
-1.7
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARHLF buys
0
MRK buys
0
No recent congressional trades found for ARHLF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARHLFMRK
Forward yield4081.63%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$8719444271720.67M$56.8K
Annual income after 10y$8,318,530,940,671,060,000.00$9,798.13
Total dividends collected$8692118457864.92M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ARHLF vs MRK ($10,000, DRIP)

YearARHLF PortfolioARHLF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$418,863$408,163.27$11,206$366.19+$407.7KARHLF
2$16,426,184$15,977,999.82$12,650$502.35+$16.41MARHLF
3$603,178,663$585,602,646.51$14,407$694.19+$603.16MARHLF
4$20,742,277,165$20,096,875,995.50$16,585$967.82+$20742.26MARHLF
5$668,079,295,177$645,885,058,611.16$19,342$1,363.89+$668079.28MARHLF
6$20,156,938,897,298$19,442,094,051,458.24$22,913$1,947.19+$20156938.87MARHLF
7$569,789,128,300,076$548,221,203,679,967.06$27,662$2,823.89+$569789128.27MARHLF
8$15,092,777,737,792,038$14,483,103,370,510,956.00$34,159$4,173.35+$15092777737.76MARHLF
9$374,685,356,121,130,900$358,536,083,941,693,400.00$43,337$6,308.80+$374685356121.09MARHLF
10$8,719,444,271,720,669,000$8,318,530,940,671,060,000.00$56,776$9,798.13+$8719444271720.61MARHLF

ARHLF vs MRK: Complete Analysis 2026

ARHLFStock

archTIS Limited designs and develops products, solutions, and services for secure information sharing and collaboration in Australia and internationally. It provides Kojensi Saas platform, which enables private and public sector organizations to share and collaborate on files in a secure space; Kojensi Enterprise that allows multi-level, multi-coalition, and multi-domain collaboration on classified information; and Kojensi Field, which allows military, government, and aid and emergency service workers to collaborate in the field. The company also offers NC Protect, which provides real time, attribute-based access, sharing control, and data-centric security collaboration applications, including Microsoft Office 365, SharePoint Online and on-premises, OneDrive, Teams, Yammer, and Exchange emails, as well as Nutanix Files, Dropbox, and Windows File Shares. In addition, it provides Axiomatics Policy Server, a software for enterprise-wide externalized dynamic authorization that delivers with attribute-based access control (ABAC); SmartGuard that securely shares data assets with dynamic authorization; Axiomatics Data Access Filter, a policy-driven dynamic data filtering and masking solution for relational databases, on-premise, and cloud; APIS and microservices; Appsian Security Platform that protects ERP data; and Appsian360, which delivers actionable insights that enables ERP data security and compliance. archTIS Limited was incorporated in 2006 and is headquartered in Barton, Australia.

Full ARHLF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this ARHLF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARHLF vs SCHDARHLF vs JEPIARHLF vs OARHLF vs KOARHLF vs MAINARHLF vs JNJARHLF vs ABBVARHLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.